Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zenas BioPharma (ZBIO) Accounts Payables (2023 - 2025)

Zenas BioPharma has reported Accounts Payables over the past 3 years, most recently at $7.1 million for Q4 2025.

  • Quarterly results put Accounts Payables at $7.1 million for Q4 2025, down 58.5% from a year ago — trailing twelve months through Dec 2025 was $7.1 million (down 58.5% YoY), and the annual figure for FY2025 was $7.1 million, down 58.5%.
  • Accounts Payables for Q4 2025 was $7.1 million at Zenas BioPharma, up from $6.4 million in the prior quarter.
  • Over the last five years, Accounts Payables for ZBIO hit a ceiling of $20.0 million in Q1 2025 and a floor of $5.4 million in Q4 2023.
  • Median Accounts Payables over the past 3 years was $7.9 million (2025), compared with a mean of $11.3 million.
  • Biggest five-year swings in Accounts Payables: surged 217.57% in 2024 and later tumbled 58.5% in 2025.
  • Zenas BioPharma's Accounts Payables stood at $5.4 million in 2023, then surged by 217.57% to $17.1 million in 2024, then tumbled by 58.5% to $7.1 million in 2025.
  • The last three reported values for Accounts Payables were $7.1 million (Q4 2025), $6.4 million (Q3 2025), and $7.9 million (Q2 2025) per Business Quant data.